Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
NCT Number: NCT01771627
This pilot clinical trial studies varenicline or nicotine patch in promoting smoking cessation among current smokers. Varenicline or nicotine patch may help people stop smoking
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Buffalo, New York, 14263, United States
PRIMARY OBJECTIVES:
I. To determine if mail delivery of 12 weeks of varenicline results in improved smoking cessation outcomes relative to nicotine replacement therapy (NRT) in 300 smokers.
II. To determine if delivery of varenicline is cost-effective as compared to nicotine patch.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo general smoking cessation counseling and receive varenicline orally (PO) twice daily (QD) on days 1-28. Courses repeat every 28 days for up to 12 weeks.
ARM II: Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.
After completion of study treatment, patients are followed up at 4 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Given PO
Other names: Champix, Chantix, CP-526555
Other names: NicoDerm CQ, nicotine skin patch, nicotine transdermal patch, nicotine transdermal system patch
Time frame: 4 months
The quit rate at 4 months will be compared between the 2 groups, using a logistic regression analysis with a 2-side 95% confidence interval.
Roswell Park Cancer Institute
Other
Pilot Study of Varenicline vs. Nicotine Patch Delivered by a Telephone Quitline to Promote Smoking Cessation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737288
Behavior, Chemically-Induced Disorders
Izmir, Turkey (Türkiye)
View Trial DetailsNCT03950427
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial DetailsNCT04417595
Chemically-Induced Disorders, Female Urogenital Diseases and Pregnancy Complications
Nashville, Tennessee, United States
View Trial DetailsNCT04033237
Chemically-Induced Disorders, Mental Disorders
Lexington, Kentucky, United States
View Trial Details